Fact-checked by Grok 2 weeks ago

Indegene

Indegene Limited is a technology-led, digital-first life sciences company founded in 1998 and headquartered in , . It provides end-to-end solutions that combine deep domain expertise in healthcare with advanced technology and operational capabilities to support , emerging biotech, and companies in commercializing their products globally. The company offers services across the product lifecycle, including enterprise commercial execution, medical and regulatory transformation, clinical development, pharmacovigilance, and data analytics powered by AI and machine learning. Indegene operates through 20 offices and nine operational hubs in regions such as North America, Europe, and Asia, employing approximately 5,200 professionals as of September 2025. Its client base includes all 20 of the top global biopharmaceutical companies, with 76 active clients contributing to a consolidated revenue of ₹28,393 million in fiscal year 2024-25. Indegene achieved a major milestone in May 2024 with its on the National Stock Exchange and , listing under the symbols NSE: INDGN and BSE: 544172. The company has expanded through strategic acquisitions, such as Cult Health LLC in 2022 for healthcare marketing expertise and Trilogy Writing & Consulting in 2024 to bolster capabilities. Recognized as a leader in Everest Group's PEAK Matrix® Assessment 2025 for Life Sciences and Analytics Services, Indegene continues to innovate in omnichannel engagement and -driven insights for the life sciences sector.

History

Founding

Indegene was established in 1998 in (formerly ), , as a pharmaceutical consultancy firm focused on the life sciences sector. The company was founded by Anand Kiran, Dr. Sanjay Parikh, Gaurav Kapoor, Dr. , and Manish Gupta, professionals with expertise in life sciences, pharmaceuticals, and . From its , Indegene's mission centered on delivering research and commercialization services to companies, drawing on deep in clinical and commercial operations to support drug marketing, content creation, and advisory needs. Early operations were bootstrapped amid funding challenges during the dot-com era, with subsequent support from Nadathur Investments in 2005 to bolster expansion efforts.

Growth and acquisitions

Indegene entered the market in 2005 by establishing its initial operations in , marking a pivotal step in its international expansion. This move allowed the company to directly serve North American clients in the life sciences sector, leveraging its expertise in and services. The company's growth accelerated through a series of strategic acquisitions that enhanced its capabilities in training, education, marketing, and analytics. In 2005, Indegene acquired Medsn, a U.S.-based provider of pharmaceutical sales training solutions, to bolster its service offerings for global clients. This was followed in 2006 by the acquisition of MedCases, a U.S.-based medical e-learning solutions company, which expanded Indegene's portfolio in . Subsequent deals further diversified Indegene's expertise. In 2012, it acquired the multi-channel e-detailing and physician services business of Aptilon, a Canadian company, for approximately $4 million, integrating advanced marketing assets and proprietary technology. In 2014, Indegene purchased Total Therapeutic Management, an Atlanta-based firm specializing in healthcare quality improvement, outcomes research, and clinician engagement, to strengthen its commercialization services. Indegene continued its acquisition strategy into the late 2010s and beyond, focusing on data and consulting capabilities. The 2019 acquisition of DT Associates, a U.K.-based and consulting firm valued at $10 million, enabled end-to-end enterprise solutions for customer excellence in life sciences. In 2021, it acquired Medical Marketing Economics, a U.S.-based leader in , , and strategies, for $10 million, enhancing its advisory services for clients. The company further expanded in 2022 with the acquisition of Cult Health LLC, a U.S.-based firm specializing in healthcare marketing and omnichannel engagement, to enhance its creative and digital marketing capabilities. In 2024, Indegene acquired Trilogy Writing & Consulting GmbH, a Germany-based provider of medical writing and regulatory services, to strengthen its capabilities in scientific communications and regulatory affairs. In 2025, Indegene pursued high-impact deals to integrate advanced technologies and . On March 25, it acquired MJL Communications Group Ltd and MJL Advertising Limited, U.K.-based firms focused on and in life sciences, to bolster its services. On October 1, it acquired BioPharm Communications, an AI-driven and adtech firm from Omnicom Health Group, for $106 million, adding capabilities in , creative , and personalized targeting for pharmaceutical , particularly in . On October 17, Indegene acquired WARN & Co., a U.K.-based transformation , for approximately £3 million, to scale its life sciences consulting practice and support large-scale operational changes. By 2025, Indegene had completed a total of 13 acquisitions, strategically building expertise in , , , and consulting to drive its global expansion. To support this growth, the company launched a new delivery center in , , during fiscal year 2025, enhancing its operational capacity for life sciences services.

Initial public offering

Indegene Limited launched its (IPO) on May 6, 2024, and it closed on May 8, 2024, with shares priced in a band of ₹430 to ₹452 per share. The IPO comprised a fresh issue of ₹760 and an offer for sale of ₹1,081.76 , raising a total of ₹1,841.76 (approximately $220 million), and the shares were listed on the National Stock Exchange (NSE: INDGN) and (BSE) on May 13, 2024. The proceeds from the fresh issue were intended for repayment or prepayment of debt incurred by Indegene's material subsidiary, ILSL Holdings, Inc., funding capital expenditure requirements for the company and its subsidiaries, pursuing inorganic growth through acquisitions, and meeting general corporate purposes. Regulatory filings for the IPO included the Draft Red Herring Prospectus (DRHP) submitted to the Securities and Exchange Board of India (SEBI) in December 2022, followed by the Red Herring Prospectus in April 2024 and the final Prospectus in May 2024. The IPO received strong investor reception, with overall subscription reaching 70.26 times, driven by qualified institutional buyers (QIBs) at 192.72 times, non-institutional investors (HNIs) at 62.23 times, and retail investors at 7.8 times. On listing day, shares debuted at a significant premium, opening at ₹659.70 on the BSE (46% above the upper price band) and ₹660 on the NSE, reflecting robust market enthusiasm for Indegene's transition to a publicly traded entity. Following the listing, Indegene's shares demonstrated positive momentum, reaching an all-time high of ₹736.30 on October 1, 2024, which elevated its to approximately ₹17,700 at that peak. By late 2024, the company's market cap had stabilized around ₹14,000 amid broader market conditions, underscoring the IPO's success in establishing Indegene as a key player in the life sciences services sector.

Business operations

Core services

Indegene provides a comprehensive suite of services across the life sciences , supporting , emerging biotech, and companies from clinical development through . These offerings integrate deep domain expertise in life sciences with to accelerate and improve outcomes. In the clinical stage, Indegene's services encompass clinical trials management, including patient recruitment and engagement using real-world data to streamline operations and enhance retention. The company also manages for safety monitoring and to ensure compliance and support . solutions leverage to inform study designs, protocols, and submissions, processing vast patient datasets for actionable insights. For medical affairs, Indegene delivers services such as medical information management, scientific publications, and to facilitate compliant communications with healthcare stakeholders. These include streamlined processes for medical, legal, and regulatory materials, alongside support for to produce regulatory and scientific documentation efficiently. Indegene's commercial services focus on and digital-led commercialization, enabling engagement with healthcare professionals and providers through personalized strategies and data-driven insights. This includes AI-driven marketing to optimize customer journeys and patient/provider solutions that enhance adherence and health outcomes via tailored engagement models. The company's client base spans all 20 of the top global biopharma companies, along with numerous emerging biotechs and firms, underscoring its role in supporting high-impact commercialization efforts.

Global presence

Indegene has its global headquarters in , , with a major office in , , at 150 College Road West, Suite 104. The company traces its origins to , . As of September 2025, Indegene operates 20 offices and 9 operations hubs worldwide, spanning , , and . Key locations include multiple sites in the such as and , several in including , , and , and European centers in , , , , and . The company has pursued expansions to strengthen this footprint, such as opening a new delivery center in in November 2024 and a center in in September 2025. Indegene employs approximately 5,200 people globally as of September 2025, with ongoing growth to support these regional expansions. In , particularly the , the focus is on commercialization activities for clients. India serves as a hub for delivery centers handling operational support, while European and operations emphasize , clinical services, and localized market needs.

Technology integration

Indegene has developed tech-native capabilities over more than 25 years, emphasizing agile, data-driven operations to support life sciences commercialization. The company integrates advanced technologies such as (AI), , and into its platforms to enable and insights across the industry value chain. Indegene's technology platforms focus on in life sciences, including -driven solutions enhanced by the 2025 acquisition of BioPharm, which bolsters adtech capabilities for global pharmaceutical clients. These platforms also support with healthcare professionals (HCPs) and advanced to optimize commercial strategies and outcomes. For instance, Indegene's -powered social intelligence solution leverages AWS services like Amazon Bedrock and SageMaker to analyze conversations, providing actionable insights through and generative . A pivotal initiative is the launch of the platform in February 2025, an enterprise-grade generative tool tailored for life sciences to accelerate commercialization processes. streamlines content creation, medical writing, and medical-legal-regulatory (MLR) reviews by embedding domain-specific knowledge graphs and ensuring compliance with industry regulations. Indegene has also pursued strategic partnerships to advance healthcare technology solutions, such as collaborations with for efficient clinical trial recruitment in rare diseases, CliniOps to accelerate trial conduct, and for in biopharmaceutical operations. Indegene differentiates itself by combining these technologies with deep life sciences domain expertise, enabling faster therapy commercialization from strategy to execution. This integration allows clients to automate , enhance commercial operations, and improve patient engagement while maintaining contextual relevance to industry needs.

Leadership and governance

Executive team

Manish Gupta serves as the Chairman and Chief Executive Officer of Indegene, as well as one of its co-founders. With over 27 years of experience in technology-led healthcare solutions, Gupta holds a B.Tech in Mechanical Engineering from IIT (BHU) Varanasi and a PGDM from IIM Ahmedabad. He oversees the company's overall strategy, operations, and growth initiatives, guiding Indegene's expansion in life sciences commercialization. Dr. Sanjay Suresh Parikh is an Executive Vice President and Executive Director at Indegene, also a co-founder. Bringing more than 30 years of expertise in pharmaceuticals and technology-driven healthcare, Parikh earned a B.Tech in Electrical Engineering from , an M.S. in from , and a Ph.D. from . He focuses on medical affairs, executive leadership, and strategic direction, particularly in integrating technology with healthcare solutions. Anand Kiran, another co-founder, holds the position of Executive Vice President of Global Operations. With over 27 years in healthcare technology solutions, he possesses a B.Pharm and M.Pharm from . Kiran manages global delivery operations, ensuring efficient execution of services across Indegene's international footprint. Suhas Prabhu is the at Indegene, responsible for financial planning, reporting, and . With 20 years in finance, Prabhu is a from ICAI and holds a B.Com from . He plays a key role in maintaining the company's financial health and supporting strategic investments. Sameer Lal serves as Senior Vice President of Enterprise Medical Solutions and at Indegene, Inc., leading efforts in the Americas. With over 25 years in pharmaceuticals and healthcare technology, Lal holds a B.Sc, B.Sc (Tech) from the , and an from NMIMS . He drives , account management, and medical affairs services for life sciences clients in the and . Vivek Ghai is the Executive Vice President of Enterprise Commercial Solutions at Indegene, Inc., serving as Global Head of Commercialization. With more than 21 years in life sciences, including and operational , Ghai earned a B.Tech in from and an MMM from NMIMS . He leads commercialization strategies, initiatives, and in marketing solutions for global clients. Tarun Mathur serves as the at Indegene. With over 27 years of experience, including 17+ years at Indegene, he holds relevant qualifications in technology and drives the company's technology strategy and .

Board of directors

Indegene's board of directors comprises 10 members, including two and eight non-executive directors, with a focus on balancing operational leadership and independent oversight following the company's in May 2024. Manish Gupta, the company's Chairman and CEO, provides executive representation on the board, guiding strategic decisions in technology-led healthcare solutions. Dr. Sanjay Suresh Parikh also serves as an . The non-executive directors include independent directors Krishnamurthy Venugopala Tenneti, a seasoned advisor with experience in management and from institutions like and IIM Ahmedabad; Dr. Ashish Gupta, an IT expert holding a Ph.D. from Stanford and serving on boards like ; Jairaj Manohar Purandare, a and former executive at and with deep taxation and governance knowledge; Dr. Georgia Nikolakopoulou Papathomas, a pharmaceutical veteran with a Ph.D. from and prior roles at ; and Pravin Udhyavara Bhadya Rao, with 35 years in IT from . Non-executive non-independent directors include Dr. Rajesh Bhaskaran Nair, a co-founder providing advisory support, holding an MBBS from the and a PGDM from IIM Ahmedabad, with 24 years of experience in healthcare solutions; Neeraj Bharadwaj, with experience from UPenn and Harvard; and Mark Francis Dzialga, with 28 years in from Canisius College and . Post-IPO, the board structure emphasizes , long-term formulation, and in professional backgrounds, particularly in life sciences, , and , to support Indegene's growth as a listed entity. The board's policy mandates at least one director and a mix of skills relevant to the healthcare domain, ensuring balanced perspectives for oversight. Key board committees include the , chaired by Jairaj Manohar with independent and executive members for financial oversight; the Nomination and Remuneration Committee, led by Krishnamurthy Venugopala Tenneti, responsible for director appointments and compensation; and the Stakeholders' Relationship Committee, also chaired by , handling . oversight is integrated into board and audit functions to address operational and strategic risks in the life sciences sector.

Financial performance

Revenue and profitability

Indegene reported consolidated revenue of ₹2,589 (US$310 million) for 2024 (FY24), reflecting steady growth in its life sciences commercialization services. The company's for the same period stood at ₹337 (US$40 million), supported by operational efficiencies and expansion in key biopharma client engagements. In FY25, Indegene demonstrated continued momentum, with Q2 revenue reaching ₹687 , marking an 8% year-over-year (YoY) increase driven by demand in enterprise solutions. Net profit for the quarter rose to ₹102 , a 11% YoY gain, bolstered by cost optimizations despite seasonal pressures. For the full 2025 (FY25), consolidated revenue reached ₹2,839 (US$339 million), while net profit grew to ₹407 (US$48 million), achieving 20.8% YoY expansion, driven by operational efficiencies and client growth in healthcare services. In Q2 FY26 (ended September 2025), revenue increased 17.1% YoY to ₹804 , with net profit up 11.3% to ₹102 , supported by demand in offerings. Revenue streams remained concentrated, with approximately 75% derived from the top 20 clients, including major global biopharma firms, while enterprise segments showed accelerated growth through and AI-enabled offerings. Indegene maintained an almost debt-free , with negligible borrowings enhancing financial flexibility for strategic initiatives. Profitability trends highlighted robust margins, with EBITDA consistently in the 18-20% range, reflecting disciplined expense management and scalable service models. growth achieved a 67.9% CAGR over the five years preceding 2025, underscoring strong operational performance and pre-IPO value creation.

Investments and funding

In February 2021, Indegene secured a significant $200 million investment from and Brighton Park Capital Partners, marking its largest private funding round to date. This minority stake investment valued the company at approximately $700 million and was primarily aimed at accelerating as well as driving global expansion in the life sciences sector. Following its in May 2024, which raised approximately ₹1,842 including a fresh issue of ₹760 , Indegene utilized the proceeds for repayment, capital expenditures, and strategic initiatives. By 2025, the company had repaid its outstanding of ₹3,934 million using IPO funds, resulting in no significant long-term borrowings. Unutilized IPO proceeds, including investments in fixed deposits totaling around ₹980 as of March 2025, supported ongoing growth efforts, such as the $106 million acquisition of BioPharm Communications in October 2025 to enhance AI-driven marketing capabilities. Indegene's emphasizes scaling technology platforms and through targeted deployment, with a focus on inorganic growth via acquisitions while maintaining a debt-free as of 2025. This approach has enabled the company to pursue selective opportunities in and life sciences consulting without relying on additional .

References

  1. [1]
    [PDF] Annual Report 2023-24 - Investor Relations | Indegene
    Aug 12, 2024 · Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging ...
  2. [2]
    About Us | Who We Are - Indegene
    Indegene Limited is the tech-native, life sciences specialist orchestrating the path from commercialization strategy through execution. Trusted by 20 of the ...
  3. [3]
    Indegene Ltd - Company Profile and News - Bloomberg Markets
    Indegene Limited operates as a life sciences commercialization company. The Company offers enterprise commercial, medical transformation, data and analysis.
  4. [4]
    Indegene - 2025 Company Profile & Team - Tracxn
    Oct 31, 2025 · Company Details ; Founded Year. 1998 ; Location. Princeton, United States ; Stage. Public ; Total Funding. $255M in 4 rounds ; Latest Funding Round.Missing: headquarters | Show results with:headquarters
  5. [5]
    Indegene Private Limited Asset Profile | Preqin
    Founded in 1998 and based in Bengaluru, India, Indegene Private Limited is a provider of digital transformation services to the life sciences industry.
  6. [6]
    Our Story - Indegene
    Indegene was founded in 1998 by Anand Kiran, Dr Sanjay Parikh, Gaurav Kapoor, Dr Rajesh Nair, and Manish Gupta. It expanded to the US in 2005, Europe in 2007, ...
  7. [7]
    How Manish Gupta Built Indegene into a $220M Pharma Services ...
    Feb 3, 2023 · In 2016, Manish Gupta did something almost unthinkable in India's startup ecosystem. With $52 million in revenue, solid profitability, and term ...Missing: history | Show results with:history
  8. [8]
    How Indegene Is Leading Healthcare Solutions For Pharma Majors ...
    Mar 30, 2020 · Founded in 1998 by Dr Rajesh Nair, Anand Kiran, Manish Gupta, Dr. Sanjay Parikh and Gaurav Kapoor, Indegene started out as a pharma marketing & ...Missing: initial | Show results with:initial
  9. [9]
    indegene Company Profile Funding & Investors | YourStory
    Indegene was founded in 1998 by Dr. Rajesh Nair and four of his associates namely Rajesh Nair, Sanjay Parikh, Anand Kiran, and Gaurav Kapoor.
  10. [10]
    How we supported Indegene's international initiatives - HSBC Group
    May 19, 2025 · Indegene was founded in 1998, a challenging time, Suhas recalls, as the company fought funding and resource struggles amid the “dot-com boom ...
  11. [11]
    Indegene acquires US medical education co - The Economic Times
    Sep 17, 2005 · Indegene Lifesystems, a medical education and marketing services company, has acquired Medsn, a US-based medical education & marketing company.
  12. [12]
    Indegene to Acquire the Multi-channel, e-Detailing and Physician ...
    Nov 9, 2012 · Indegene to Acquire the Multi-channel, e-Detailing and Physician Marketing Services Business Assets of Canada-based Aptilon, to Help Clients ...Missing: Medsn MedCases
  13. [13]
    Indegene to acquire Canada-based company for $4 million
    Nov 19, 2012 · Indegene will acquire the multi-media marketing assets including the proprietary technology of the Canadian company, Aptilon, all valued around ...Missing: Medsn MedCases
  14. [14]
    Indegene acquires Total Therapeutic Management | News
    The global marketing solutions firm Indegene has bought Total Therapeutic Management (TTM). The addition of Atlanta-based TTM will expand ...
  15. [15]
    Indegene Strengthens US Healthcare Market Presence Through ...
    Jan 2, 2014 · Indegene Strengthens US Healthcare Market Presence Through Acquisition of Atlanta-based Total Therapeutic Management, Inc. News provided by.
  16. [16]
    Indegene Acquires DT Associates, Provides End-To-End Enterprise ...
    Indegene acquired DT Associates to provide end-to-end solutions for customer excellence, from measuring maturity to designing commercial models.
  17. [17]
    Indegene Acquires DT Associates, Provides End-to-end Enterprise ...
    Sep 4, 2019 · DT Associates will operate as a separate entity in Indegene Private Ltd, as 'DT Consulting' effective immediately. "Right now, we see Life ...
  18. [18]
    Indegene strengthens its Pricing, Reimbursement and Market ...
    Indegene, a technology-led healthcare solutions provider, today announced the acquisition of Medical Marketing Economics, LLC (MME), a global leader in Pricing ...
  19. [19]
    Indegene strengthens its Pricing, Reimbursement and Market
    Indegene strengthens its Pricing, Reimbursement and Market Access capabilities with Medical Marketing Economics, LLC acquisition. August 30, 2021 12:00 ET | ...
  20. [20]
    Indegene Announces Acquisition of BioPharm to Expand AI-Driven ...
    Indegene Announces Acquisition of BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma. 01 Oct 2025 ...
  21. [21]
    Indegene acquires digital peer BioPharm for $106 million - ET Pharma
    Oct 3, 2025 · Indegene acquires digital peer BioPharm for $106 million. According to a stock exchange filing, Indegene will acquire the company's 100 per cent ...
  22. [22]
    Indegene Strengthens Consulting Practice to Accelerate Life ...
    Oct 17, 2025 · Indegene has steadily expanded its consulting capabilities over the past decade. The acquisition of DT Consulting in 2020 strengthened the ...
  23. [23]
    Indegene Acquires Warn & Co for £3M to Boost Life Sciences
    Oct 17, 2025 · The company confirmed that its wholly owned subsidiary, Indegene Ireland Limited, signed a Share Purchase Agreement (SPA) on October 16, 2025, ...
  24. [24]
    Indegene: Leading Digital Life Sciences Transformation | AlphaStreet
    Sep 22, 2025 · Across its history, Indegene has executed 13 acquisitions, expanding its global footprint and strengthening vertical expertise. Recent deals ...
  25. [25]
    Indegene Expands Global Delivery Network, Announces A New ...
    Nov 18, 2024 · Indegene, a digital-first life sciences commercialization company, announced a new center in Hyderabad to strengthen its global delivery operations.Missing: FY | Show results with:FY
  26. [26]
    [PDF] Indegene Limited Q3 & 9M FY-25 Earnings Conference Call
    Jan 31, 2025 · Heading into calendar year '25, this seems to be a year of cautious recovery for the industry. Many of you would have tracked the narrative from ...Missing: founded | Show results with:founded
  27. [27]
    Indegene Ltd IPO 2024 Price, Date, Review and Key Insights
    Indegene Ltd - IPO ; Min Investment (₹). ₹ 14,916.00 ; Listing Exchange. MumbaiNSE ; Open Date. 06-May-2024 ; Close Date. 08-May-2024 ; Listing Date. 13-May-2024 ...
  28. [28]
    Indegene IPO: Check opening date, GMP, price band, other details
    May 3, 2024 · Indegene Limited's initial public offering (IPO) is set to open on May 6, 2024, with an aim to raise Rs 1,841.76 crore.
  29. [29]
    https://alphastreet.com/india/indegene-leading-digital-life-sciences-transformation/
  30. [30]
    Indegene files DRHP with SEBI for IPO - The Hindu
    Dec 15, 2022 · Indegene files DRHP with SEBI for IPO. The funds raised through the IPO are proposed to be utilised for debt repayment/prepayment, capital ...
  31. [31]
    Indegene IPO : Insightful Analysis You Must know | Kotak Securities
    Rating 4.4 (171,000) IPO Details and Objectives ... The company plans to use the funds obtained from fresh issues to: Fund its capex requirements; Repay and prepay debt of its ...
  32. [32]
    [PDF] INDEGENE LIMITED - BSE
    Dec 16, 2022 · The Offer is being made pursuant to Regulation 6(2) of the Securities and Exchange Board of India (Issue of Capital and Disclosure.
  33. [33]
    [PDF] in the nature of abridged prospectus - JP Morgan India Private Limited
    This is an abridged prospectus containing salient features of the Red Herring Prospectus of Indegene Limited ("Company") dated April 26, 2024 (the.
  34. [34]
    Indegene IPO day 3: GMP, subscription status, review, other details ...
    May 8, 2024 · As per the Indegene IPO subscription status, the public issue has been fully subscribed and it has received strong response from investors across segments.
  35. [35]
    Indegene IPO listing: Shares make strong debut; list at 46% premium
    May 13, 2024 · The company intends to use capital raised from the issuance of fresh equities to fund the repayment of debts of one of its material subsidiaries ...
  36. [36]
    NSE:INDGN — TradingView - Indegene Limited
    INDGN reached its all-time high on Oct 1, 2024 with the price of 736.30 INR, and its all-time low was 470.10 INR and was reached on Jun 4, 2024. View more price ...
  37. [37]
    INDEGENE LIMITED (INDGN.NS) Stock Historical Prices & Data
    INDEGENE LIMITED (INDGN.NS) ; Dec 17, 2024, 584.10, 604.00 ; Dec 16, 2024, 595.10, 595.10 ; Dec 13, 2024, 601.00, 601.50 ; Dec 12, 2024, 590.00, 605.10 ...Missing: late | Show results with:late
  38. [38]
    Enterprise Clinical Solutions | Indegene
    ### Summary of Enterprise Clinical Solutions by Indegene
  39. [39]
    Enterprise Medical Solutions | Indegene
    ### Summary of Enterprise Medical Solutions (Focus: Medical Affairs and Related Services)
  40. [40]
    Enterprise Commercial Solutions | Indegene
    ### Summary of Indegene’s Enterprise Commercial Solutions
  41. [41]
    Contact Us - Indegene
    Indegene, Inc. 150 College Rd W Suite 104. Princeton NJ 08540 (Princeton Forrestal Village) Tel: +1 732 750 2901. Los Angeles. Indegene, Inc. 4500 Park Granada ...
  42. [42]
    Indegene expands India footprint, opens new centre in Pune
    Sep 8, 2025 · Monday, September 8, 2025 ... Indegene has about 5,000 employees worldwide, 9 operations hubs and 20 offices across North America, Europe, and ...
  43. [43]
    Indegene Expands Footprint in Europe, Launches New Entity in Spain
    Feb 6, 2025 · With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene's client base includes the world's top 20 biopharma ...
  44. [44]
    Indegene Partners with Datavant to Revolutionize Clinical Trial ...
    Sep 19, 2025 · With approximately 5,000 employees worldwide, Indegene operates across: 9 operations hubs; 20 offices spanning North America, Europe, and Asia ...
  45. [45]
    Indegene Expands Presence In Europe, Announces New Center in ...
    Mar 19, 2025 · The company already has a significant presence in Europe, with centers in Germany, Ireland, and Switzerland. Last year, Indegene acquired ...Missing: workforce | Show results with:workforce
  46. [46]
    Life Sciences Technology Solutions | Indegene
    Indegene delivers comprehensive life sciences technology solutions with AI-first platform services, digital engineering, deep tech transformation, ...
  47. [47]
    Indegene: Digital-first life sciences commercialization company
    Indegene Limited is the tech-native, life sciences specialist orchestrating the path from commercialization strategy through execution. · Enterprise Commercial ...
  48. [48]
    How Indegene's AI-powered social intelligence for life sciences ...
    Aug 12, 2025 · This post will explore how Indegene is using services like Amazon Bedrock, Amazon SageMaker, and purpose-built AWS solutions for healthcare and ...
  49. [49]
    Indegene Launches Cortex, A Fit-For-Purpose Generative AI ...
    Feb 24, 2025 · Indegene, a digital-first, life sciences commercialization company, launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the ...
  50. [50]
    Cortex - Indegene
    Cortex is Indegene's enterprise-grade Generative AI platform, purpose-built for the life sciences industry. It enables the development and scaling of ...
  51. [51]
    Datavant and Indegene Partner to Power More Efficient Clinical Trial ...
    Sep 19, 2025 · Datavant and Indegene announce strategic collaboration to enhance patient recruitment for clinical trials, with a focus on rare disease and ...
  52. [52]
    CliniOps Announces Strategic Partnership with Indegene to ...
    Jan 9, 2025 · Together, CliniOps and Indegene aim to deliver a joint vision of accelerating clinical trial conduct by redefining industry standards. As part ...
  53. [53]
    Indegene | Snowflake Partners
    Indegene is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop ...
  54. [54]
    Leadership - Investor Relations | Indegene
    A senior executive in healthcare communications for the past 31 years, Jim co-founded CultHealth, a full-service, healthcare marketing agency for many life ...
  55. [55]
    Sameer Lal - SVP, Business Development at Indegene - The Org
    Sameer heads a portfolio in Account Management, covering the United States and Europe. He has been associated with Indegene for over 10 years.
  56. [56]
    [PDF] Corporate Governance Report - Q1'25 - Investor Relations | Indegene
    Jul 30, 2024 · IPO Committee. Executive ... The meetings of the board of directors and the above committees have been conducted in the manner as specified.
  57. [57]
    Leadership | Who We Are - Indegene
    Dr. Sanjay Suresh Parikh. Executive Director and Executive Vice President. Dr. Sanjay holds a bachelor of technology degree in electrical ...Missing: backgrounds Anand Kiran
  58. [58]
    Pravin Rao, Dr. Ashish Gupta and Jairaj Purandare join ... - Indegene
    Pravin Rao, Dr. Ashish Gupta and Jairaj Purandare join Indegene's Board of Directors and elevate its corporate governance practices | News | Indegene.
  59. [59]
    [PDF] Policy On Board Diversity - Investor Relations | Indegene
    Apr 28, 2025 · NRC is responsible for reviewing and assessing the composition of the Board and will make recommendations to the Board on the appointment of new ...
  60. [60]
    [PDF] Investor Presentation and Fact Sheet – Q2 FY2025
    Further, the revenue from our Top 5 accounts have grown 2.3% sequentially. Suhas Prabhu, Chief Financial Officer – Our earnings growth in Q2FY25 continues with ...
  61. [61]
    Indegene Ltd. - Quarterly Results and Financial Statement as of Sep ...
    Annual Net Profit Indegene Ltd. Mar-2025 Annual Net Profit is Rs 181 Cr which is growth of 31.5% YoY. ; EBIDTPCT_A. EBITDA Ann. margin %. 0.2% ; INT_A. Interest ...Missing: pre- | Show results with:pre-
  62. [62]
    [PDF] “Indegene Limited Q2 FY '26 Earnings Conference Call” October 31 ...
    Oct 31, 2025 · Further, on October 16, 2025, we also completed the acquisition of WARN & CO, a boutique. U.K.-based consulting business for upfront ...Missing: total | Show results with:total
  63. [63]
    INDEGENE LTD. 2024-25 Annual Report Analysis - Equitymaster
    Jun 2, 2025 · The revenues of INDEGENE LTD. stood at Rs 29,465 m in FY25, which was up 10.5% compared to Rs 26,659 m reported in FY24. INDEGENE LTD.'s revenue ...
  64. [64]
    Indegene Ltd share price - Screener
    Market Cap ₹ 12,281 Cr. Current Price ₹ 511; High / Low ₹ 694 / 485; Stock P/E 27.6; Book Value ₹ 119; Dividend Yield 0.39 %; ROCE 24.8 %; ROE 20.6 %; Face ...
  65. [65]
    Bengaluru-based Indegene gets $200 million in funding
    Feb 4, 2021 · Bengaluru-based Indegene gets $200 million in funding. Shilpa ... Founded in 1998 by five first generation entrepreneurs, Indegene has ...Missing: initial | Show results with:initial<|control11|><|separator|>
  66. [66]
    Indegene IPO price band fixed at ₹430-452 per share - The Hindu
    Apr 29, 2024 · Indegene Ltd. announces IPO opening on May 6, 2024, with price band of ₹430-₹452 per share, raising funds for growth.
  67. [67]
    [PDF] ADD Indegene
    Sep 10, 2025 · Debt of INR 3,934mn has been paid off with IPO proceeds in FY24. The company, currently, has no long-term borrowings. • DSO-billed has been ...
  68. [68]
    Indegene Ltd Q4 Results Highlights - Torus Digital
    Apr 29, 2025 · Utilisation of IPO Proceeds​​ As of March 31, 2025, unutilised net proceeds include ₹980 crore invested in fixed deposits, ₹41 crore held in the ...Missing: utilization | Show results with:utilization
  69. [69]
    Indegene plans more acquisitions to expand global operations - MSN
    Digital healthcare technology company Indegene is expanding its global operations and building an acquisition pipeline to support future growth.Missing: regional | Show results with:regional